Abstract
Background: Although genistein has been reported to exert its anti-tumor activity, the exact mechanism of its action is poorly elucidated. Recently, it has been found that genistein could regulate the expression of microRNAs. Therefore, our aim in the present study was to find whether genistein regulates specific miR-27a in pancreatic cancer cells.
Methods: We performed our studies using multiple methods including MTT assay, RT-PCR, Western blotting analysis, migration, invasion assay, and transfection.
Results: We observed that genistein significantly inhibited the expression of miR-27a in pancreatic cancer cells. Moreover, inhibition of miR-27a suppressed cell growth and induced apoptosis as well as inhibited invasion in pancreatic cancer cells. Furthermore, we found a synergy effect between miR-27a and genistein on cell growth inhibition, apoptosis, and invasion, suggesting that targeting miR-27a may represent a potential strategy for treatment of pancreatic cancer.
Conclusions: Our findings demonstrated that genistein plays a tumor suppressor role in part through inhibition of miR-27a in pancreatic cancer cells.
Keywords: Genistein, miR-27a, FOXO1, apoptosis, cell growth, pancreatic cancer.
Current Pharmaceutical Design
Title:Genistein Inhibits Cell Growth and Invasion Through Regulation of miR-27a in Pancreatic Cancer Cells
Volume: 20 Issue: 33
Author(s): Jun Xia, Long Cheng, Chuanzhong Mei, Jia Ma, Ying Shi, Fanpeng Zeng, Zhenghuan Wang and Zhiwei Wang
Affiliation:
Keywords: Genistein, miR-27a, FOXO1, apoptosis, cell growth, pancreatic cancer.
Abstract: Background: Although genistein has been reported to exert its anti-tumor activity, the exact mechanism of its action is poorly elucidated. Recently, it has been found that genistein could regulate the expression of microRNAs. Therefore, our aim in the present study was to find whether genistein regulates specific miR-27a in pancreatic cancer cells.
Methods: We performed our studies using multiple methods including MTT assay, RT-PCR, Western blotting analysis, migration, invasion assay, and transfection.
Results: We observed that genistein significantly inhibited the expression of miR-27a in pancreatic cancer cells. Moreover, inhibition of miR-27a suppressed cell growth and induced apoptosis as well as inhibited invasion in pancreatic cancer cells. Furthermore, we found a synergy effect between miR-27a and genistein on cell growth inhibition, apoptosis, and invasion, suggesting that targeting miR-27a may represent a potential strategy for treatment of pancreatic cancer.
Conclusions: Our findings demonstrated that genistein plays a tumor suppressor role in part through inhibition of miR-27a in pancreatic cancer cells.
Export Options
About this article
Cite this article as:
Xia Jun, Cheng Long, Mei Chuanzhong, Ma Jia, Shi Ying, Zeng Fanpeng, Wang Zhenghuan and Wang Zhiwei, Genistein Inhibits Cell Growth and Invasion Through Regulation of miR-27a in Pancreatic Cancer Cells, Current Pharmaceutical Design 2014; 20 (33) . https://dx.doi.org/10.2174/1381612820666140128215756
DOI https://dx.doi.org/10.2174/1381612820666140128215756 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-inflammatory, Antioxidant, Lung and Liver Protective Activity of
<i>Galaxaura oblongata</i> as Antagonistic Efficacy against LPS using Hematological
Parameters and Immunohistochemistry as Biomarkers
Cardiovascular & Hematological Agents in Medicinal Chemistry Important Anti-Cancer Applications of Protein Based Nanoparticles
Current Proteomics Recently Patented Applications of Homologous Cellular and Extracellular Agents as Therapeutics or Targets for the Prevention of Restenosis Post- Angioplasty
Recent Patents on Cardiovascular Drug Discovery Reversal of Tumor Induced Dendritic Cell Paralysis: A Treatment Regimen Against Cancer
Current Immunology Reviews (Discontinued) Metabolomics Analysis for Biomarker Discovery: Advances and Challenges
Current Medicinal Chemistry Cytokine/Antibody Complexes: An Emerging Class of Immunostimulants
Current Pharmaceutical Design Prediction of the Ebola Virus Infection Related Human Genes Using Protein-Protein Interaction Network
Combinatorial Chemistry & High Throughput Screening Therapeutic Strategies to Target Multiple Kinases in Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1
Current Pharmaceutical Design Bortezomib as an Antitumor Agent
Current Pharmaceutical Biotechnology A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
Current Medicinal Chemistry Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Exploiting EPR in Polymer Drug Conjugate Delivery for Tumor Targeting
Current Pharmaceutical Design Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Current Cancer Drug Targets DNA Instability at Chromosomal Fragile Sites in Cancer
Current Genomics Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews